American Neurological Association (ANA): ATH434 Preserves Dopaminergic Neurons, Reduces α-synuclein Oligomerization, and Improves Motor Function in a Transgenic Murine Multiple System Atrophy Model


0

likes

0

questions

0

company answers

Ask a question


Your question will be sent privately to Alterity Therapeutics. The company may choose to make this question public.

Investor Q&As

Start the conversation

Ask Alterity Therapeutics a question about this update.